| Publications: |
| Synthesis: |
|---|
| Reported Utilities: Alzheimer’s disease, epilepsy and cerebral ischemiaTHis info has no place in the database. Probably need a comment field under application.Also, I am not sure if Mallinckrodt supplies both the I-125 and I-123 labeled versions. Zea-Ponce Y, Baldwin RM, Zoghbi SS, Innis RB. Formation of 1-[123I]iodobutane in labeling [123I]iomazenil by iododestannylation: implications for the reaction mechanism. Appl Radiat Isot. 1994; 45(1):63-68Kaji T, Kuge Y, Yokota C, Tagaya M, Inoue H, Shiga T, Minematsu K, Tamaki N. Characterisation of [123I]iomazenil distribution in a rat model of focal cerebral ischaemia in relation to histopathological findings. Eur J Nucl Med Mol Imaging. 2004; 31(1):64-70. Specific activity reported: 57-463 GBq/mg seems like this info should be in its own field |
| In vitro analysis: |
|---|
| Millet P, Graf C, Buck A, Walder B, Ibanez V. Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters. Neuroimage. 2002; 17(2):928-942.Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994; 35(2):228-238Kaji T, Kuge Y, Yokota C, Tagaya M, Inoue H, Shiga T, Minematsu K, Tamaki N. Characterisation of [123I]iomazenil distribution in a rat model of focal cerebral ischaemia in relation to histopathological findings. Eur J Nucl Med Mol Imaging. 2004; 31(1):64-70. |
| Animal Studies: |
|---|
| Kaji T, Kuge Y, Yokota C, Tagaya M, Inoue H, Shiga T, Minematsu K, Tamaki N. Characterisation of [123I]iomazenil distribution in a rat model of focal cerebral ischaemia in relation to histopathological findings. Eur J Nucl Med Mol Imaging. 2004; 31(1):64-70.Kuge Y, Hikosaka K, Seki K, Ohkura K, Nishijima KC, Kaji T, Ueno S, Tsukamoto E, Tamaki N. Characteristic brain distribution of 1-(14)C-octanoate in a rat model of focal cerebral ischemia in comparison with those of (123)I-IMP and (123)I-iomazenil. J Nucl Med. 2003; 44(7):1168-1175.Morimoto K, Watanabe T, Ninomiya T, Hirao T, Tanaka A, Onishi T, Tamagami H. Quantitative evaluation of central-type benzodiazepine receptors with [(125)I]Iomazenil in experimental epileptogenesis: II. The rat cortical dysplasia model. Epilepsy Res. 2004; 61(1-3):113-118.Kurokawa K, Jibiki I, Matsuda H, Fukushima T, Tsuji S, Yamaguchi N, Hisada K. Comparison of benzodiazepine receptor and regional cerebral blood flow imaging of epileptiform foci in hippocampal kindle... |
| Clinical Studies: |
|---|
| Dong Y, Fukuyama H, Nabatame H, Yamauchi H, Shibasaki H, Yonekura Y. Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission computed tomography in patients with ischemic cerebrovascular disease. A comparison with PET study. Stroke. 1997; 28(9):1776-1782.Dey HM, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Smith EO, Zubal IG, Zea-Ponce Y, Olson C, Charney DS. Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. J Nucl Med. 1994; 35(3):399-404.Verhoeff NP, Busemann Sokole E, Hengst D, Stubbs JB, van Royen EA. Dosimetry of iodine-123 iomazenil in humans. Eur J Nucl Med. 1993; 20(7):580-584. |
|
|---|
